Leading research into ME/CFS

Company Name

Accessing the biobank

Academic and commercial researchers will be able to apply to use samples and/or data from the UK ME/CFS Biobank if they present a sound scientific rationale for the proposed study and have a good research track record. Eligible researchers must be supported by their institution.

All research proposals intending to use samples from the UK ME/CFS Biobank must be developed in line with the Biobank’s mission; proposals intending to develop the following types of studies will be prioritised:

  • testing or generating new hypotheses on the mechanisms (pathophysiology) of ME/CFS
  • improving diagnosis (biomarkers) and phenotyping, and/or
  • basic science, e.g. pharmacological in vitro studies potentially leading to clinical trials on therapeutic approaches.

Over 500 participants have been included in this study.  ME/CFS participants have been diagnosed by physicians and are compliant with CDC ’94 (Fukuda) and/or Canadian Consensus Criteria (CCC); case definition compliance are available for four other commonly-used criteria.  Samples are available from four groups of participants:

  • Mild and moderate ME/CFS
  • Severe (home/bed-bound) ME/CFS
  • Multiple sclerosis
  • Healthy controls